Content about treatment for multiple sclerosis

March 27, 2013

The Food and Drug Administration has approved a new treatment for multiple sclerosis made by Biogen Idec, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for multiple sclerosis made by Biogen Idec, the agency said Wednesday.

The FDA announced the approval of Tecfidera (dimethyl fumarate) capsules for adults with relapsing forms of MS.

January 28, 2013

FDA accepts application for Genzyme MS drug

The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

CAMBRIDGE, Mass. — The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

Genzyme, a division of French drug maker Sanofi, said the FDA accepted its application seeking approval for Lemtrada (alemtuzumab) for relapsing MS. The company expects the agency to decide whether to approve the drug in the second half of this year.

November 14, 2011

Genzyme announces phase-3 results of Lemtrada in patients with relapsing MS

A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

CAMBRIDGE, Mass. — A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

Genzyme, acquired earlier this year by French drug maker Sanofi, announced results of the phase-3 "CARE-MS II" trial of Lemtrada (alemtuzumab), saying the drug "significantly reduced" worsening of disability and relapse in patients with MS, compared with Rebif (interferon beta-1a), made by Pfizer and German drug maker Merck KGaA, a separate company from U.S.-based Merck.